Nevirapine Milpharm

Nevirapine, the active ingredient in Nevirapine Milpharm, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as a tablet for oral use. It treats HIV-1 infection in adults and adolescents. GNH USA supplies Nevirapine Milpharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is an antiretroviral medication that targets the HIV‑1 reverse transcriptase enzyme, forming part of combination therapy for viral suppression. - HIV‑1 infection: reduces viral load and helps restore immune function when used with other antiretrovirals.

Nevirapine may cause a range of adverse reactions, from mild to severe. Monitoring and prompt reporting of symptoms are essential.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional upset stomach. - Fatigue: feeling unusually tired. - Headache: mild to moderate intensity. - Diarrhoea: loose stools. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic failure: signs of liver dysfunction such as jaundice. - Severe hypersensitivity: swelling, fever, or breathing difficulty. - Hepatotoxicity: elevated liver enzymes indicating injury. - Neutropenia: reduced white blood cell count increasing infection risk. - Life‑threatening rash: extensive skin involvement.

Nevirapine requires careful monitoring due to its potential for liver and skin toxicity. - Liver monitoring: perform baseline and periodic liver function tests. - Rash assessment: examine any skin changes promptly. - Avoid potent CYP3A4 inducers: drugs like rifampicin may lower nevirapine levels. - Caution in hepatitis B/C: patients with pre‑existing liver disease need close observation. - Pregnancy considerations: weigh maternal benefits against potential fetal risks. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nevirapine interacts with several medicines that can alter its effectiveness or increase toxicity.

Major Interactions (Avoid): - Rifampicin: reduces nevirapine plasma concentrations. - St. John’s wort: strong CYP3A4 inducer that lowers drug levels. - Carbamazepine: may decrease nevirapine exposure.

Moderate Interactions (Monitor Closely): - Efavirenz: combined NNRTIs can increase risk of liver toxicity. - Protease inhibitors (e.g., ritonavir): may raise nevirapine concentrations, requiring dose adjustment.